Action of the Vidaza on the Atrial Fibrillation (AVIFA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03298321|
Recruitment Status : Unknown
Verified October 2019 by Hospices Civils de Lyon.
Recruitment status was: Recruiting
First Posted : October 2, 2017
Last Update Posted : October 16, 2019
|Condition or disease||Intervention/treatment|
|Atrial Fibrillation Acute Leukemia||Other: Effect of Vidaza treatment|
|Study Type :||Observational|
|Estimated Enrollment :||14 participants|
|Official Title:||Action of the Vidaza on the Atrial Fibrillation|
|Actual Study Start Date :||December 20, 2018|
|Estimated Primary Completion Date :||December 20, 2021|
|Estimated Study Completion Date :||December 20, 2021|
This study will be performed on adults with Acute Myeloid Leukemia and atrial fibrillation. Only patients treated for the first time with vidaza® within an hospital hematology unit will be included.
Other: Effect of Vidaza treatment
The goal of this study is to evaluate the effects of azacytidine on arrhythmia and left atrium fibrosis.
- Evolution of atrial arrhythmic events [ Time Frame: Maximum 12 months ]Evolution of the atrial arrhythmic events observed in the inclusion, 6 months or 12 months (according to the frequency of follow-up of the atrial fibrillation) after the beginning of the cure by Holter-ECG.
- Evolution of the morphology and the fibrosis atrial [ Time Frame: Maximum 12 months ]Evolution of the morphology and the fibrosis atrial observed in the inclusion, 6 months or 12 months (according to the frequency of follow-up of the atrial fibrillation) after the beginning of the cure by transthoracic echocardiography.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03298321
|Contact: Philippe CHEVALIER, MD||04 72 35 76 89 ext +email@example.com|
|Contact: Camille VALLA||04 27 85 62 69 ext +firstname.lastname@example.org|
|Service de rythmologie - GH Est-Hôpital Louis Pradel - CHU de Lyon HCL||Recruiting|
|Bron, France, 69229|
|Contact: Philippe CHEVALIER, MD 04 72 35 76 89 ext +33 email@example.com|
|Contact: Camille VALLA 04 27 85 62 69 ext +33 firstname.lastname@example.org|
|Principal Investigator: Philippe CHEVALIER, MD|
|Centre Léon Berard||Recruiting|
|Lyon, France, 69008|
|Contact: Anne-Sophie Michallet, MD, PhD 04.78.78.26.41 ext +33 email@example.com|
|Principal Investigator: Anne-Sophie Michallet, MD, PhD|
|Hopital Lyon Sud||Recruiting|
|Pierre-Bénite, France, 69310|
|Contact: Pierre-Yves COURAND, MD, PhD 04.78.86.57.37 ext +33 firstname.lastname@example.org|
|Contact: Fiorenza Barraco, MD, PhD 04.78.86.43.40 ext +33 email@example.com|
|Principal Investigator: Pierre-Yves COURAND, MD, PhD|
|Sub-Investigator: Fiorenza Barraco, MD, PhD|